Rosetta Genomics (ROSG), Sheba Medical Center Enter MicroRNA-Based BiomarkerResearch Collaboration
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Rosetta Genomics Ltd. (Nasdaq: ROSG) announces that the Company has entered into a research agreement with Sheba Medical Center at Tel HaShomer, Israel, to develop a microRNA-based signature to predict response to Nivolumab, an immunotherapy drug marketed as Opdivo, which is approved for the treatment of lung cancer patients.
The prospective study, “Circulating microRNA Biomarkers for Lung Cancer Patient Response to the Drug Nivolumab when Administered as Second Line”,” will be led by Jair Bar, M.D., Deputy Director-Institute of Oncology, Sheba Medical Center, and will include collection of whole blood, peripheral blood mononuclear cells (PBMCs) and serum samples. Rosetta will use its proprietary microarray design and qRT-PCR platform to identify miRNAs associated with response. The primary endpoint of the study is prediction of Objective Response Rate (ORR) as measured by tumor radiologic response to the immunotherapy (RECIST 1.1 response rate at 6 months.) The secondary endpoint of the project is to predict survival benefit of advanced non-small cell lung cancer (NSCLC) from immunotherapy as measured by Overall Survival (OS) and OS rate (12 and 24 months).
“Immunotherapy is a promising tool in the treatment of lung cancer. We are still at the early phases of understanding who will benefit from immunotherapy, which is making a big difference for a subgroup of 23-30% of the patients. For this reason, we are excited to be collaborating with Rosetta Genomics to identify blood biomarkers that will predict which patients will benefit from immunotherapy with Nivolumab. Our aim is to develop a test that offers a potentially powerful method of identifying markers to measure the status of the immune system and other biological events. Our goal is to be able to accurately predict which patients should receive immunotherapy and which patients would receive larger benefit from other treatment modalities,” concluded Dr. Bar.
“microRNAs are key regulators of immune system and have been shown to directly target and inhibit PD-1 and PDL-1 in various cancers. Their important biological role as well as high stability in the circulation makes them excellent candidates for predicting response to these breakthrough drugs. We have conducted early clinical research that has demonstrated microRNAs’ potential as predictive biomarkers in immuno-oncology,” stated Dganit Bar, Ph.D., Chief Scientific Officer of Rosetta Genomics. “Our goals for this collaboration with Sheba Medical dovetail with earlier work we conducted in partnership with large pharmaceutical companies that focused on establishing biomarkers to identify responders to certain immuno-oncology drugs.”
“The development of a new microRNA biomarker signature to predict response to Opdivo in lung cancer patients fits well with our comprehensive lung-specific menu that assists in diagnosis, prognosis, and prediction to therapy for lung cancer patients. This menu includes a full array of lung-specific biomarkers via FISH, PCR, and IHC, OncoGxLung (utilizing NGS), and mi-LUNG, a proprietary microRNA diagnostic test for differentiating between the 4 main subtypes of lung cancer. We look forward to advancing this collaboration with Sheba Medical Center on the development of a new microRNA biomarker signature that can better predict patient response to Opdivo and other PD-1 and PD-1 inhibitors in lung cancer patients,” noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.
Opdivo® is a registered trademark of Bristol-Myers Squibb.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shire's (SHPG) Phase 3 Investigational Study of VONVENDI Meets Primary Endpoint in Controlling Bleeding in Adults with VWD
- PICO Holdings (PICO) Announces Leadership, Governance Changes; Terminates Central Square Agreement
- MarketAxess Holdings (MKTX) Announces Monthly Performance Results for November 2016
Create E-mail Alert Related CategoriesCorporate News, FDA
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!